Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tavokinogene telseplasmid - OncoSec Medical

Next Previous
Drug Profile

Tavokinogene telseplasmid - OncoSec Medical

Alternative Names: 12-NGVL331; DNA IL-12; IL-12 gene therapy; IL-12 plasmid; IL-12-gene-therapy-Inovio; Immunopulse; ImmunoPulse; ImmunoPulse®IL-12; Interleukin-12 gene therapy; intratumoral pIL-12-EP; LipoVIL12; OMS ElectroImmunotherapy™; pIL-12; pIL-12 Electroporation; Plasmid-based interleukin-12 or pIL-12; pUMVC3-hIL; Tavo-EP; TAVOPLUS; Tavo™

Latest Information Update: 26 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inovio Biomedical Corporation
  • Developer Fred Hutchinson Cancer Research Center; H. Lee Moffitt Cancer Center and Research Institute; Massachusetts General Hospital; Merck Sharp & Dohme; OncoSec Medical; University of California at San Francisco; University of Washington
  • Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies; Interleukins
  • Mechanism of Action Gene transference; Immunostimulants; Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cutaneous T-cell lymphoma; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Triple negative breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 16 May 2023 OncoSec Medical plans a phase II trial for Neoadjuvant melanoma (Neoadjuvant therpay, Combination therapy)
  • 15 May 2023 OncoSec Medical completes Type C meeting with the US FDA
  • 03 Apr 2023 Safety and adverse events data from a phase II trial in Malignant melanoma released by OncoSec Medical
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top